Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Emavusertib in combination with azacitidine and venetoclax in patients with AML

Claudio Cerchione • 31 May 2024
ASCO 2024
Acute Myeloid Leukemia Leukemia Azacitidine Emavusertib Venetoclax

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the combination of azacitidine and venetoclax with the IRAK4 inhibitor emavusertib for the treatment of acute myeloid leukemia (AML). This triplet combination is currently being investigated in a Phase I clinical trial, with the hopes of improving outcomes for elderly patients with AML who currently have a poor prognosis. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Claudio Cerchione

Looking forward to the second edition of the MYELOMAS international meeting
2:40
Looking forward to the second edition of the MYELOMAS international meeting
Claudio Cerchione • 13 Oct 2026
Insights into what to expect at the 2026 MYELOMAS meeting
2:09
Insights into what to expect at the 2026 MYELOMAS meeting
Claudio Cerchione • 13 Oct 2026
Addressing unmet needs in multiple myeloma: a preview of the MYELOMAS meeting
1:42
Addressing unmet needs in multiple myeloma: a preview of the MYELOMAS meeting
Claudio Cerchione • 13 Oct 2026
Tailoring treatment to all patient profiles in transplant-ineligible newly diagnosed myeloma
1:58
Tailoring treatment to all patient profiles in transplant-ineligible newly diagnosed myeloma
Claudio Cerchione • 23 Sep 2026

Related Videos

How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals